TRENDING: You Don't Have To Dig Far To Cash In On Rare EarthsTwo of Biogen's (BIIB) key growth drivers, Leqembi and Skyclarys, hit snags in the third-quarter. But Biogen stock yo-yoed and, most recently, edged down slightly.Sales of Friedreich's ataxia treatment, Skyclarys, came in at $133 million, slightly below calls ranging between$136 million to $140 million, RBC Capital Markets analyst Brian Abrahams said. Leqembi, the Eisai (ESAIY)-partnered Alzheimer's drug, generated$69 million in U.S. sales. That ...